Abstract
The aryl hydrocarbon receptor (AHR) plays an important role during mammalian embryo development. Inhibition of AHR signaling promotes the development of hematopoietic stem/progenitor cells. AHR also regulates the functional maturation of blood cells, such as T cells and megakaryocytes. However, little is known about the role of AHR modulation during the development of erythroid cells. In this study, we used the AHR antagonist StemRegenin 1 (SR1) and the AHR agonist 2, 3, 7, 8-tetrachlorodibenzo- p- dioxin (TCDD) during different stages of human erythropoiesis to elucidate the function of AHR. We found that antagonizing AHR signaling improved the production of human embryonic stem cell (hESC)-derived erythrocytes and enhanced erythroid terminal differentiation. RNA-sequencing showed that SR1 treatment of proerythroblasts upregulated the expression of erythrocyte differentiation-related genes and downregulated actin organization-associated genes. We found that SR1 promoted F-actin remodeling in terminally differentiated erythrocytes, favoring the maturation of the cytoskeleton and enucleation. We demonstrated that the effects of AHR inhibition on erythroid maturation resulted from an increase in F-actin remodeling. Our findings help uncover the mechanism for AHR-mediated human erythroid cell differentiation. We also provide a new approach toward the large-scale production of functionally mature hPSC-derived erythrocytes for use in translational applications.
Introduction
Generating a sustainable, lab-grown supply of red blood cells (erythrocytes) from human pluripotent stem cells (hPSCs) is a major goal for regenerative medicine. While current protocols can successfully differentiate stem cells into early-stage blood cells, they often encounter a "maturation wall" at the final stages of erythropoiesis. Terminal differentiation requires massive structural changes, including hemoglobin synthesis, cytoskeletal remodeling, and enucleation—the ejection of the nucleus to become a flexible, functional erythrocyte. This study investigates the Aryl Hydrocarbon Receptor (AHR) as a potential molecular brake on this process, demonstrating that its inhibition via the small-molecule antagonist SR1 can double enucleation rates and improve the quality of lab-grown blood.
Methods
The researchers utilized a multi-staged differentiation approach using H1 human embryonic stem cells (hESCs) and CD34+ cells from umbilical cord blood (UCB). hESCs were first differentiated into hematopoietic stem/progenitor cells (HSPCs) using an AGM-S3 co-culture system.
AHR signaling was modulated using SR1 (antagonist) and TCDD (agonist) at specific developmental windows. The team employed flow cytometry to monitor lineage markers (GPA, CD71, CD34, CD45), colony-forming unit (CFU) assays to assess progenitor potential, and multi-omics (RNA-seq and proteomics) to map the molecular shifts. Functional quality was assessed through deformability tests and immunofluorescence of F-actin remodeling.
Key Results and Insights
Promotion of Erythroid Progenitors
AHR inhibition was found to be most effective during the transition from early erythroid progenitors (BFU-E) to terminal stages. SR1 treatment significantly expanded the pool of various hematopoietic progenitors, as evidenced by increased colony counts in GEMM, BFU-E, and CFU-E assays compared to DMSO controls.
Enhanced Terminal Maturation and Enucleation
Beyond progenitor expansion, SR1 treatment resulted in a 2-fold increase in the percentage of enucleated erythroid cells. This was driven by the downregulation of actin organization genes, which facilitates the necessary F-actin ring remodeling and polarization required for nuclear ejection. Furthermore, SR1-derived erythrocytes exhibited higher hemoglobin concentrations and superior deformability indices, behaving more like natural human blood.
Molecular Mechanism
RNA-seq and proteomic analysis confirmed that AHR inhibition upregulates genes essential for hemoglobin synthesis (AHSP, ALAS2) and membrane stability (SLC4A1). Conversely, activating AHR with TCDD impaired these processes, confirming AHR's role as a negative regulator of terminal erythroid differentiation.
Discussion
This study identifies AHR inhibition as a powerful tool for overcoming the maturation barriers in in vitro erythropoiesis. By facilitating F-actin remodeling and metabolic priming, SR1 treatment produces more mature and functional erythrocytes. While these results are promising for large-scale blood production, future work must evaluate the long-term survival of these cells in vivo and address the scalability costs of the multi-phase culture system. Additionally, the potential role of oxidative stress in accelerating this maturation process warrants further investigation to ensure cell longevity.
Summary updated